Document Detail


Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia.
MedLine Citation:
PMID:  22584777     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In 1977, a 5-year-old girl diagnosed with acute lymphoblastic leukemia was treated on Dana-Farber Cancer Institute Childhood Acute Lymphoblastic Leukemia Protocol 77-01, receiving a cumulative doxorubicin dose of 465 mg/m(2), cranial radiation, and other drugs. After being in continuous complete remission for 34 months, she developed heart failure and was treated with digoxin and furosemide. At 16 years of age, she was diagnosed and treated for dilated cardiomyopathy. Over the years, she continued to have bouts of heart failure, which became less responsive to treatment. At 36 years of age, she received a heart transplant. Six months later, she stopped taking her medications and suffered a sudden cardiac death.
Authors:
John M Goldberg; Rebecca E Scully; Stephen E Sallan; Steven E Lipshultz
Related Documents :
18791407 - Potential uses of computed tomography for management of heart failure patients with dys...
21320527 - Characterization of a rat hypoxia-ischemia model where duration of hypoxia is determine...
21451207 - Pharmacological doses of melatonin reduce the glycosaminoglycan level within the infarc...
22332157 - Trends in the incidence of acute kidney injury in patients hospitalized with acute myoc...
9801247 - Update on myocardial contrast echocardiography: a surgeon's perspective.
20435207 - Hemodynamic results and changes in myocardial function after transcatheter aortic valve...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of pediatric hematology/oncology     Volume:  34     ISSN:  1536-3678     ISO Abbreviation:  J. Pediatr. Hematol. Oncol.     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-06-20     Completed Date:  2012-08-29     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  9505928     Medline TA:  J Pediatr Hematol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  395-7     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, University of Miami Leonard M Miller School of Medicine, Miami, FL 33101, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibiotics, Antineoplastic / adverse effects*
Child, Preschool
Doxorubicin / adverse effects*
Female
Heart Failure / chemically induced*
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Grant Support
ID/Acronym/Agency:
AI50274/AI/NIAID NIH HHS; CA068484/CA/NCI NIH HHS; CA127642/CA/NCI NIH HHS; HD052102/HD/NICHD NIH HHS; HD052104/HD/NICHD NIH HHS; HD80002/HD/NICHD NIH HHS; HL004537/HL/NHLBI NIH HHS; HL007188/HL/NHLBI NIH HHS; HL053392/HL/NHLBI NIH HHS; HL072705/HL/NHLBI NIH HHS; HL078522/HL/NHLBI NIH HHS; HL079233/HL/NHLBI NIH HHS; HL087000/HL/NHLBI NIH HHS; HL087708/HL/NHLBI NIH HHS; HL094100/HL/NHLBI NIH HHS; HL095127/HL/NHLBI NIH HHS; R01 CA079060-02/CA/NCI NIH HHS; R01 CA079060-03/CA/NCI NIH HHS; R01 CA079060-04/CA/NCI NIH HHS; R01 CA079060-05/CA/NCI NIH HHS; R01 CA079060-06/CA/NCI NIH HHS; R01 CA127642-01A1/CA/NCI NIH HHS; R01 CA127642-02/CA/NCI NIH HHS; R01 CA127642-03/CA/NCI NIH HHS; R01 HL053392-05/HL/NHLBI NIH HHS; R01 HL053392-05S1/HL/NHLBI NIH HHS; R01 HL053392-05S2/HL/NHLBI NIH HHS; R01 HL053392-06A1/HL/NHLBI NIH HHS; R01 HL053392-07/HL/NHLBI NIH HHS; R01 HL053392-08/HL/NHLBI NIH HHS; R01 HL053392-09/HL/NHLBI NIH HHS; R01 HL053392-10/HL/NHLBI NIH HHS; R01 HL053392-11/HL/NHLBI NIH HHS; R01 HL053392-12/HL/NHLBI NIH HHS; R01 HL053392-13/HL/NHLBI NIH HHS; R01 HL053392-14/HL/NHLBI NIH HHS; R01 HL053392-15/HL/NHLBI NIH HHS; R01 HL072705-01/HL/NHLBI NIH HHS; R01 HL072705-02/HL/NHLBI NIH HHS; R01 HL072705-03/HL/NHLBI NIH HHS; R01 HL072705-04/HL/NHLBI NIH HHS; R01 HL072705-05/HL/NHLBI NIH HHS; R01 HL072705-06/HL/NHLBI NIH HHS; R01 HL078522-01/HL/NHLBI NIH HHS; R01 HL078522-02/HL/NHLBI NIH HHS; R01 HL078522-03/HL/NHLBI NIH HHS; R01 HL078522-04/HL/NHLBI NIH HHS; R01 HL078522-05/HL/NHLBI NIH HHS; R01 HL109090-01A1/HL/NHLBI NIH HHS; R13 HL087708-01/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 23214-92-8/Doxorubicin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Predictive Value of Interleukin-5 and Monocyte Chemotactic Protein-1 for Bacteremia in Children With...
Next Document:  Necrotizing Fasciitis Caused by Serratia marcescens After Venous Access Port Implantation in a Child...